| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Serono Pharmaceutical Research Institute, Geneva, Switzerland;
Istituto di Ricerche Biomediche "A. Marxer," LCG-RBM/Serono Discovery, I-10010. Colleretto Giacosa, Italy;
University of Regensburg, Department of Internal Medicine, Regensburg, Germany; and
The Sackler Institute of Pulmonary Pharmacology, King’s College London, London, United Kingdom
A hallmark of autoimmunity and other chronic diseases is the overexpression of chemokines resulting in a detrimental local accumulation of proinflammatory immune cells. Chemokines play a pivotal role in cellular recruitment through interactions with both cell surface receptors and glycosaminoglycans (GAGs). Anti-inflammatory strategies aimed at neutralizing the chemokine system have to-date targeted inhibition of the receptor-ligand interaction with receptor antagonists. In this study, we describe a novel strategy to modulate the inflammatory process in vivo through mutation of the essential heparin-binding site of a proinflammatory chemokine, which abrogates the ability of the protein to form higher-order oligomers, but retains receptor activation. Using well-established protocols to induce inflammatory cell recruitment into the peritoneal cavity, bronchoalveolar air spaces, and CNS in mice, this non-GAG binding variant of RANTES/CCL5 designated [44AANA47]-RANTES demonstrated potent inhibitory capacity. Through a combination of techniques in vitro and in vivo, [44AANA47]-RANTES appears to act as a dominant-negative inhibitor for endogenous RANTES, thereby impairing cellular recruitment, not through a mechanism of desensitization. [44AANA47]-RANTES is unable to form higher-order oligomers (necessary for the biological activity of RANTES in vivo) and importantly forms nonfunctional heterodimers with the parent chemokine, RANTES. Therefore, although retaining receptor-binding capacity, altering the GAG-associated interactive site of a proinflammatory chemokine renders it a dominant-negative inhibitor, suggesting a powerful novel approach to generate disease-modifying anti-inflammatory reagents.
This article has been cited by other articles:
|
|
 |
|
  V. Braunersreuther, S. Steffens, C. Arnaud, G. Pelli, F. Burger, A. Proudfoot, and F. Mach A Novel RANTES Antagonist Prevents Progression of Established Atherosclerotic Lesions in Mice Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1090 - 1096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shahrara, A. E. I. Proudfoot, C. C. Park, M. V. Volin, G. K. Haines, J. M. Woods, C. H. Aikens, T. M. Handel, and R. M. Pope Inhibition of Monocyte Chemoattractant Protein-1 Ameliorates Rat Adjuvant-Induced Arthritis J. Immunol., March 1, 2008; 180(5): 3447 - 3456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Alexander-Brett and D. H. Fremont Dual GPCR and GAG mimicry by the M3 chemokine decoy receptor J. Exp. Med., December 24, 2007; 204(13): 3157 - 3172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sutton, V. Friand, D. Papy-Garcia, M. Dagouassat, L. Martin, R. Vassy, O. Haddad, O. Sainte-Catherine, M. Kraemer, L. Saffar, et al. Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells Mol. Cancer Ther., November 1, 2007; 6(11): 2948 - 2958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yang, X. Liao, M. K. Agarwal, L. Barnes, P. E. Auron, and G. R. Stark Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NF{kappa}B Genes & Dev., June 1, 2007; 21(11): 1396 - 1408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Ellyard, L. Simson, A. Bezos, K. Johnston, C. Freeman, and C. R. Parish Eotaxin Selectively Binds Heparin: AN INTERACTION THAT PROTECTS EOTAXIN FROM PROTEOLYSIS AND POTENTIATES CHEMOTACTIC ACTIVITY IN VIVO J. Biol. Chem., May 18, 2007; 282(20): 15238 - 15247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Murphy, Y. Cho, A. Sachpatzidis, C. Fan, M. E. Hodsdon, and E. Lolis Structural and Functional Basis of CXCL12 (Stromal Cell-derived Factor-1{alpha}) Binding to Heparin J. Biol. Chem., March 30, 2007; 282(13): 10018 - 10027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Harvey, P. Mellor, H. Eldaly, T. W.J. Lennard, J. A. Kirby, and S. Ali Inhibition of CXCR4-Mediated Breast Cancer Metastasis: A Potential Role for Heparinoids? Clin. Cancer Res., March 1, 2007; 13(5): 1562 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. V. Campanella, J. Grimm, L. A. Manice, R. A. Colvin, B. D. Medoff, G. R. Wojtkiewicz, R. Weissleder, and A. D. Luster Oligomerization of CXCL10 Is Necessary for Endothelial Cell Presentation and In Vivo Activity J. Immunol., November 15, 2006; 177(10): 6991 - 6998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. T. Murooka, M. M. Wong, R. Rahbar, B. Majchrzak-Kita, A. E. I. Proudfoot, and E. N. Fish CCL5-CCR5-mediated Apoptosis in T Cells: REQUIREMENT FOR GLYCOSAMINOGLYCAN BINDING AND CCL5 AGGREGATION J. Biol. Chem., September 1, 2006; 281(35): 25184 - 25194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yu, M. D. Sweeney, O. M. Saad, S. E. Crown, T. M. Handel, and J. A. Leary Chemokine-Glycosaminoglycan Binding: SPECIFICITY FOR CCR2 LIGAND BINDING TO HIGHLY SULFATED OLIGOSACCHARIDES USING FTICR MASS SPECTROMETRY J. Biol. Chem., September 16, 2005; 280(37): 32200 - 32208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Veldkamp, F. C. Peterson, A. J. Pelzek, and B. F. Volkman The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin Protein Sci., April 1, 2005; 14(4): 1071 - 1081. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
